MedySapiens

MedySapiens, Inc. provides diagnosis and care services for newborns with rare diseases hospitalized in NICUs (Neonatal Intensive Care Unit) usually in large hospitals with AI-driven Genomics technologies.
Our two main technologies are 1. Diagnostic panel which detects actionable and relatively common rare genetic diseases, about 220 of them out of total existing 7,000+, 2. Genetic variant analysis software solution, MedyCVi® (MedySapiens’ Cloud for Variant interpretation) which applies ACMG (American College of Medical Genetics) guidelines with 3 main modules of AI technologies.
MedySapiens was established in 2017 and currently has 19 full-time employees. So far, we have raised about $7.7M and we are eyeing for additional $20M for series-B.
For the Korean domestic market, we are taking advantage of our “Social” spirit and are heavily working with government’s public procurement office. For international markets, especially US, we are setting up pathology and NGS labs for hospitals.